A Phase 2, Randomized, Double-blind, Placebo-controlled, 24-Week Study to Evaluate the Efficacy, Safety, and Tolerability of BBT-877, as Mono- or add-on Therapy, in Patients With Idiopathic Pulmonary Fibrosis (IPF)
Latest Information Update: 04 Apr 2025
At a glance
- Drugs BBT 877 (Primary)
- Indications Idiopathic pulmonary fibrosis
- Focus Therapeutic Use
- Sponsors Bridge Biotherapeutics
Most Recent Events
- 27 Mar 2025 Status changed from active, no longer recruiting to completed.
- 19 Feb 2025 Planned End Date changed from 17 Sep 2025 to 23 Feb 2025.
- 30 Dec 2024 According to a Bridge Biotherapeutics media release, topline data from this study expected in April 2025.